U.S. Animal Health Market By Product (Biologics, Pharmaceuticals, Medicinal Feed Additives, Others), By Animal Type (Production Animals, Companion Animals), By Route of Administration (Oral, Injectable, Intravenous, Topical, Others), By Disease (Porcine Diseases, Poultry Diseases, Cattle Diseases, Aquaculture Diseases, Others), By Distribution Channel (Retail, E-Commerce, Hospital/ Clinic Pharmacy), By Region, Competition, Forecast and Opportunities, 2021-2031F

Key Insights	Details
Forecast Period	2027-2031
Market Size (2025)	USD 13.38 Billion
CAGR (2026-2031)	8.41%
Fastest Growing Segment	Pharmaceuticals
Largest Market	Mid-West
Market Size (2031)	USD 21.72 Billion

Market Overview

The United States Animal Health Market will grow from USD 13.38 Billion in 2025 to USD 21.72 Billion by 2031 at a 8.41% CAGR. The United States animal health market encompasses a diverse range of products and services, including pharmaceuticals, vaccines, diagnostics, and veterinary care, dedicated to preventing, treating, and controlling diseases in both companion and food-producing animals. Main drivers supporting market expansion include increasing pet humanization leading to higher discretionary spending on pet healthcare, a growing demand for animal protein necessitating robust livestock health management, and continuous advancements in veterinary medical treatments. According to the American Veterinary Medical Association, the US dog population reached 89.7 million and the cat population totaled 73.8 million in 2024, signifying a substantial and growing base for companion animal health demand.

A significant challenge impeding market expansion involves the escalating costs associated with advanced veterinary treatments and products. This factor can lead to pet owners deferring or foregoing necessary care due to financial constraints. According to the North American Pet Health Insurance Association, Gross Written Premiums for pet insurance in the U.S. surpassed a record $4.7 billion in 2024, reflecting a 21.4% increase from the prior year, highlighting a growing reliance on insurance to manage these rising expenses.

Key Market Drivers

Pet humanization and premium-care spending driving growth
The United States animal health market is significantly driven by increasing pet humanization and a willingness among owners to spend on premium care. As pets are increasingly viewed as integral family members, owners are prioritizing their health and well-being, leading to greater demand for advanced veterinary services, specialized treatments, and higher-quality products. This behavioral shift fuels market expansion through consistent spending patterns on preventive care, diagnostics, and therapeutics. According to the American Pet Products Association (APPA), in its 2026 State of the Industry Report released March 2026, U.S. pet industry expenditures reached $158 billion in 2025. This substantial investment underscores the profound impact of pet humanization on the market’s growth trajectory.

Technological advances in veterinary medicine propel growth
Further market growth is propelled by continuous advancements in veterinary medical technologies. Innovations in diagnostics, pharmaceuticals, and treatment protocols enable more effective disease management and improved animal welfare. These technological strides offer veterinarians enhanced tools to provide superior care, ranging from sophisticated imaging to novel therapeutic agents. For instance, according to the U.S. Food and Drug Administration (FDA) Center for Veterinary Medicine, in December 2025, the first drug to delay congestive heart failure in dogs received approval, highlighting a key development in animal pharmaceutical care. Collectively impacting the market, annual revenue per veterinary practice averaged approximately $2.7 million in 2025, according to VetSource, as reported by the American Veterinary Medical Association in February 2026. These technological leaps not only expand the scope of available treatments but also contribute to the overall valuation of the animal health sector.

Download Free Sample Report

Key Market Challenges

Rising Veterinary Costs Impede Growth and Care Utilization
The escalating costs associated with advanced veterinary treatments and products represent a significant impediment to the growth of the United States animal health market. This financial burden directly leads to pet owners deferring or foregoing necessary veterinary care, impacting both the health outcomes for animals and the market's potential expansion.

Financial Constraints Drive Care Deferral and Revenue Growth through Higher Prices
According to a 2025 national survey of U.S. pet owners commissioned by PetSmart Charities and conducted by Gallup, over half, specifically 52%, of dog and cat owners reported skipping or declining recommended veterinary care in the preceding year. Among these individuals, 71% attributed their decision to financial considerations. This trend is further underscored by observations from the American Veterinary Medical Association. John Volk, a senior consultant with Brakke Consulting, indicated that in 2025, veterinary prices increased faster than overall inflation. Concurrently, national veterinary practices experienced a decline in client visits by approximately 3%, despite modest revenue increases of about 2.5%. This demonstrates that market revenue growth is increasingly reliant on higher prices for services rather than a greater volume of patient visits. Such dynamics directly restrict the overall demand for veterinary services and products, thereby hampering market expansion.

Key Market Trends

Rising Diagnostics and Point-of-Care Testing Reshape U.S. Animal Health
The increased adoption of advanced diagnostics and point-of-care testing represents a pivotal trend reshaping the United States animal health market. These innovations enable veterinarians to achieve faster, more accurate disease detection and streamline treatment protocols for both companion and food-producing animals. This advancement facilitates early intervention, enhancing animal welfare and productivity. For instance, in livestock, rapid identification and containment of widespread diseases are paramount. According to AVMA reports from February 2025, over 1000 cattle herds from over 16 states were estimated to suffer from the Avian influenza virus type A (H5N1) outbreak, underscoring the critical need for efficient diagnostic tools in managing health crises.

Practice Consolidation and Corporate Ownership Transform Veterinary Services
Another significant transformation within the United States animal health market is the ongoing consolidation of veterinary practices and the rise of corporate ownership. This trend is altering the competitive landscape, influencing operational efficiencies and the scope of veterinary services. Corporate entities often possess greater capital for investment in advanced equipment, technology, and specialized staff, which can lead to enhanced service offerings. However, it also presents challenges for independent practices regarding market share. According to PMC, May 2025, approximately 75% of specialty and emergency practices and 25% of primary care practices, representing 50% of nationwide veterinary revenues, are owned by corporate consolidators. This shift centralizes ownership and impacts pricing strategies and care delivery.

Segmental Insights

Pharmaceuticals Drive Growth in the U.S. Animal Health Market
The United States Animal Health Market is experiencing significant expansion, with the Pharmaceuticals segment emerging as a key driver of growth. This rapid acceleration is primarily attributed to continuous advancements in veterinary medicine, leading to the development of novel and more effective therapeutics for both companion and production animals. Increasing pet humanization has driven owners to invest more in advanced treatments and preventive medications for chronic and infectious diseases in pets. Concurrently, the rising focus on sustainable livestock production and stringent food safety standards necessitates robust pharmaceutical interventions for disease prevention and control in commercial animals. Furthermore, ongoing innovations, including targeted therapies and new product approvals by regulatory bodies like the U.S. Food and Drug Administration, are continually expanding treatment options and fueling market growth.

Regional Insights

Mid-West: Leader in the US animal health market, driven by livestock concentration and innovation
The Mid-West region leads the United States Animal Health Market, primarily driven by its central and indispensable role in the nation's vast agricultural and livestock industries. This area is a significant hub for extensive cattle, poultry, and swine farming operations, necessitating robust animal health solutions. The substantial concentration of livestock creates a critical demand for advanced disease prevention, management strategies, and overall animal well-being to maintain productivity and ensure food supply sustainability. Furthermore, the presence of various veterinary schools, research institutions, and specialized animal health companies within the Mid-West fosters innovation and the delivery of essential services. Regulatory bodies such as the Food and Drug Administration Center for Veterinary Medicine (FDA-CVM) and the United States Department of Agriculture (USDA) ensure high standards for animal health products in this vital agricultural region.

Recent Developments

• In May 2025, Merck Animal Health announced the commercial availability of ARMATREX™ (silane quaternary ammonium salt), an EPA-registered spray-on antimicrobial solution, for the United States. This product launch was part of a partnership agreement with Good Salt™ Life, LLC, the product's manufacturer, with Merck Animal Health responsible for marketing and sales in the U.S. The novel solution was designed to reduce environmental pathogen loads in animal health facilities, thereby strengthening biosecurity measures. This initiative provided animal health stakeholders in the United States with an innovative tool to maintain clean environments and support the food supply chain.
• In May 2025, Merck Animal Health, a division of Merck & Co., Inc., announced an investment of $895 million to expand its manufacturing and research and development facilities in De Soto, Kansas. The capital expansion included $860 million for the existing manufacturing plant and an additional $35 million for its research and development laboratories. This significant investment in the United States Animal Health Market aimed to increase filling and freeze-dryer capacity for large molecule vaccines and biologic products, bolstering global drug discovery and development initiatives focused on novel parasiticides and therapeutics.
• In February 2025, Elanco Animal Health Incorporated introduced its new Pet Protect line of veterinarian-formulated supplements for dogs and cats in the United States. This product launch addressed the increasing consumer demand for proactive pet wellness options in the rapidly expanding U.S. pet supplement market. The comprehensive line featured science-backed solutions for various health needs, including joint health, multivitamins, Omega-3, and immune support. Elanco's expansion into this category aimed to reinforce its commitment to enhancing overall pet health and well-being with trusted, specialized products for the United States Animal Health Market.
• In June 2024, Boehringer Ingelheim and Trupanion, Inc. announced a strategic collaboration designed to enhance access to high-quality healthcare and disease prevention for pets and their owners across North America. This partnership leveraged the collective expertise and data of both companies to identify risk factors for common pet conditions earlier, supporting improved disease management. The collaboration further aimed to bolster veterinarian and consumer education, expand product offerings, and drive other initiatives within the United States Animal Health Market to support pet care throughout an animal's lifetime.

Key Market Players

• Zoetis Inc.
• Elanco Animal Health Incorporated
• Merck Animal Health (Merck & Co. Inc.)
• Boehringer Ingelheim International GmbH
• Virbac S.A.
• Ceva Santé Animale
• IDEXX Laboratories Inc.
• Dechra Pharmaceuticals plc
• Vetoquinol S.A.
• Phibro Animal Health Corporation

By Product	By Animal Type	By Route of Administration	By Disease	By Distribution Channel	By Region
Biologics Pharmaceuticals Medicinal Feed Additives Others	Production Animals Companion Animals	Oral Injectable Intravenous Topical Others	Porcine Diseases Poultry Diseases Cattle Diseases Aquaculture Diseases Others	Retail E-Commerce Hospital/ Clinic Pharmacy	Northeast Midwest South West

Report Scope:

In this report, the United States Animal Health Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• United States Animal Health Market, By Product:

• Biologics
• Pharmaceuticals
• Medicinal Feed Additives
• Others

• United States Animal Health Market, By Animal Type:

• Production Animals
• Companion Animals

• United States Animal Health Market, By Route of Administration:

• Oral
• Injectable
• Intravenous
• Topical
• Others

• United States Animal Health Market, By Disease:

• Porcine Diseases
• Poultry Diseases
• Cattle Diseases
• Aquaculture Diseases
• Others

• United States Animal Health Market, By Distribution Channel:

• Retail
• E-Commerce
• Hospital/ Clinic Pharmacy

• United States Animal Health Market, By Region:

• Northeast
• Midwest
• South
• West